Skip to main content

Table 2 Comparison of SF-12v2 score between patients with good and poor TTR

From: Time in therapeutic range, quality of life and treatment satisfaction of patients on long-term warfarin for non-valvular atrial fibrillation: a cross-sectional study

SF12v2 parameters

Total score;

Mean ± SD;

95% CI

Without adjustment

Adjusted for duration*

Adjusted for education*

Good TTF

Poor TTF

p value

Good TTF

Poor TTF

p value

Good TTF

Poor TTF

p value

Mean ± SD;

95% CI

Mean ± SD;

95% CI

Mean ± SE;

95% CI

Mean ± SE;

95% CI

Mean ± SE;

95% CI

Mean ± SE;

95% CI

PCS

47.0 ± 9.0;

45.9–48.0

48.3 ± 8.7;

46.3–50.3

46.5 ± 9.1;

45.3–47.7

0.150

48.2 ± 1.1;

46.1–50.3

46.6 ± 0.6;

45.4–47.7

0.175

47.7 ± 1.1;

45.7–49.8

46.7 ± 0.6;

45.5–47.9

0.395

MCS

53.5 ± 9.6;

52.4–54.6

53.4 ± 8.6;

51.4–55.4

53.6 ± 9.7;

52.3–54.9

0.919

53.5 ± 1.1;

51.3–55.8

53.5 ± 0.6;

52.3–54.8

0.998

53.6 ± 1.1;

51.3–55.9

53.5 ± 0.6;

52.2–54.8

0.951

PF

47.0 ± 10.6;

45.8–48.2

48.0 ± 10.9;

45.5–50.6

46.7 ± 10.5;

45.3–48.1

0.358

47.9 ± 1.2;

45.5–50.4

46.7 ± 0.7;

45.3–48.1

0.399

47.4 ± 1.2;

45.0–49.9

46.9 ± 0.7;

45.5–48.3

0.704

RP

48.2 ± 9.6;

47.1–49.3

48.6 ± 8.8;

46.5–50.6

48.1 ± 9.9;

46.8–49.4

0.684

48.6 ± 1.1;

46.3–50.8

48.1 ± 0.6;

46.8–49.3

0.698

48.2 ± 1.1;

46.0–50.5

48.2 ± 0.6;

46.9–49.4

0.968

BP

49.6 ± 10.5;

48.5–50.8

51.1 ± 9.5;

48.8–53.3

49.2 ± 10.7;

47.8–50.6

0.184

51.0 ± 1.2;

48.6–53.4

49.2 ± 0.7;

47.8–50.6

0.207

50.5 ± 1.2;

48.0–52.9

49.4 ± 0.7;

48.0–50.7

0.446

GH

47.6 ± 9.7;

46.5–48.7

47.9 ± 9.5;

45.7–50.1

47.5 ± 9.8;

46.2–48.8

0.730

47.9 ± 1.2;

45.7–50.2

47.5 ± 0.7;

46.2–48.8

0.737

48.1 ± 1.2;

45.8–50.4

47.4 ± 0.7;

46.2–48.7

0.639

V

56.3 ± 11.3;

55.0–57.6

56.9 ± 11.5;

54.2–59.6

56.1 ± 11.3;

54.6–57.6

0.602

57.0 ± 1.3;

54.3–59.6

56.1 ± 0.8;

54.6–57.5

0.561

57.1 ± 1.3;

54.5–59.7

56.0 ± 0.8;

54.5–57.5

0.505

SF

49.0 ± 10.7;

47.8–50.2

51.5 ± 7.9;

49.7–53.4

48.2 ± 11.3;

46.7–49.6

0.019

51.9 ± 1.3;

49.2–54.2

48.1 ± 0.7;

46.7–49.5

0.014

51.0 ± 1.2;

48.5–53.4

48.3 ± 0.7;

47.0–49.7

0.069

RE

48.8 ± 10.7;

47.6–50.0

48.2 ± 10.7;

45.7–50.7

49.0 ± 10.7;

47.6–50.4

0.563

48.1 ± 1.3;

45.6–50.6

49.0 ± 0.7;

47.6–50.4

0.523

48.2 ± 1.2;

45.7–50.7

49.0 ± 0.7;

47.6–50.4

0.607

MH

53.8 ± 9.9;

52.7–55.0

53.4 ± 9.3;

51.2–55.5

54.0 ± 10.1;

52.7–55.3

0.634

53.5 ± 1.2;

51.2–55.8

54.0 ± 0.7;

52.7–55.3

0.714

53.4 ± 1.2;

51.1–55.7

54.0 ± 0.7;

52.7–55.3

0.661

  1. SF12v2 short form 12v2 health survey, SD standard deviation, 95% CI 95% confidence interval, PCS physical component summary, MCS mental component summary, PF physical functioning, RP role–physical, BP bodily pain, GH general health perceptions, V vitality, SF social functioning, RE role–emotional, MH mental health
  2. *Adjusted with ANCOVA test
  3. Figures in bold are statistically significant
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us